Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer.
Humans
Oxaliplatin
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
Male
Female
Infusions, Intra-Arterial
/ methods
Peripheral Nervous System Diseases
/ chemically induced
Middle Aged
Infusions, Intravenous
Aged
Antineoplastic Agents
/ adverse effects
Hepatic Artery
Organoplatinum Compounds
/ administration & dosage
Adult
Prospective Studies
Severity of Illness Index
Neoplasm Metastasis
Dose-Response Relationship, Drug
Hepatic arterial infusion chemotherapy
Metastatic colorectal cancer
Neuropathy
Oxaliplatin
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
04
02
2024
accepted:
13
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
Oxaliplatin, a major drug in metastatic colorectal cancer (mCRC), is responsible for cumulative, dose-limiting peripheral neuropathy (PN). Whether the hepatic arterial infusion (HAI) route can limit oxaliplatin-induced PN in comparison with the intravenous (IV) route has not been specifically explored so far. We compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials. The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety. A total of 363 patients were included (IV, 300; HAI, 63). In total, 180 patients in the IV group (60%) and 30 patients in the HAI group (48%) developed clinically significant PN, with no significant difference between the two groups (p = 0.23). No difference was shown in the time to onset of PN either (p = 0.23). The administration of oxaliplatin HAI rather than IV in the treatment of mCRC does not reduce the incidence, precocity, and severity of PN.
Sections du résumé
BACKGROUND
BACKGROUND
Oxaliplatin, a major drug in metastatic colorectal cancer (mCRC), is responsible for cumulative, dose-limiting peripheral neuropathy (PN). Whether the hepatic arterial infusion (HAI) route can limit oxaliplatin-induced PN in comparison with the intravenous (IV) route has not been specifically explored so far.
METHODS
METHODS
We compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials. The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.
RESULTS
RESULTS
A total of 363 patients were included (IV, 300; HAI, 63). In total, 180 patients in the IV group (60%) and 30 patients in the HAI group (48%) developed clinically significant PN, with no significant difference between the two groups (p = 0.23). No difference was shown in the time to onset of PN either (p = 0.23).
CONCLUSION
CONCLUSIONS
The administration of oxaliplatin HAI rather than IV in the treatment of mCRC does not reduce the incidence, precocity, and severity of PN.
Identifiants
pubmed: 39283505
doi: 10.1007/s00520-024-08807-6
pii: 10.1007/s00520-024-08807-6
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Antineoplastic Agents
0
Organoplatinum Compounds
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
660Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25(4):299–303
doi: 10.1007/BF00684890
pubmed: 2295116
Oh PJ, Lee JR, Kim SK, Kim JH (2020) Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: a prospective study. Eur J Oncol Nurs 44:101676
doi: 10.1016/j.ejon.2019.101676
pubmed: 31751847
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400
doi: 10.1200/JCO.2005.03.0106
pubmed: 16421419
Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E et al (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2(1):54–58
doi: 10.3816/CCC.2002.n.011
pubmed: 12453338
Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W (2001) Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12(3):421–422
doi: 10.1023/A:1011184609963
pubmed: 11332158
Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13(1):26–32
doi: 10.1200/JCO.1995.13.1.26
pubmed: 7799029
Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483
doi: 10.1200/JCO.2002.07.061
pubmed: 12177109
Gedlicka C, Scheithauer W, Schüll B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359–3361
doi: 10.1200/JCO.2002.99.502
pubmed: 12149316
Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J et al (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6(2):146–151
doi: 10.3816/CCC.2006.n.032
pubmed: 16945171
Pfeiffer P, Lustberg M, Näsström J, Carlsson S, Persson A, Nagahama F et al (2022) Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A/POLAR-M). JNCI Cancer Spectr 6(6):pkac075
doi: 10.1093/jncics/pkac075
pubmed: 36308441
pmcid: 9678401
Agence nationale de sécurité du médicament et des produits de santé (ANSM). https://base-donnees-publique.medicaments.gouv.fr/ . Accessed 23 Aug 2024
Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–977
pubmed: 13197542
pmcid: 1942491
Kingham TP, D’Angelica M, Kemeny NE (2010) Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 102(8):988–995
doi: 10.1002/jso.21753
pubmed: 21166003
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9):1395–1403
doi: 10.1200/JCO.2005.03.8166
pubmed: 16505413
Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 3:CD007823
Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F et al (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23(22):4881–4887
doi: 10.1200/JCO.2005.05.120
pubmed: 16009952
Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D et al (2008) Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15(1):219–226
doi: 10.1245/s10434-007-9581-7
pubmed: 17896145
Malka D, Boige V, Faron M, Caramella C, Boucher E, Rivera P et al (2012) Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (IV) fluorouracil (FU), leucovorin (LV) and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM): final results of a multicenter phase 2 study (CHOICE). Ann Oncol 1(23):ix98
Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C et al (2016) Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 27(2):267–274
doi: 10.1093/annonc/mdv548
pubmed: 26578731
Gelli M, Ewald J, Tanguy ML, Passot G, Quenet F, Touchefeu Y et al (2023) Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a multicenter randomized phase II trial (PRODIGE 43 - PACHA-01). JCO 41(16_suppl):3515–3515
doi: 10.1200/JCO.2023.41.16_suppl.3515
Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H et al (2003) Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23(6D):5203–5208
pubmed: 14981990
Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer drugs 15(6):647–650
doi: 10.1097/01.cad.0000131684.06390.fe
pubmed: 15205611
Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B et al (2022) Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/− irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Dig Liver Dis 54(3):324–330
doi: 10.1016/j.dld.2021.12.012
pubmed: 35027324
Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D et al (2011) Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. Lancet Oncol 12(11):1032–1044
doi: 10.1016/S1470-2045(11)70199-1
pubmed: 21903473
Common terminology criteria for adverse events (CTCAE) | Protocol development | CTEP [Internet]. [cited 2023 Oct 28]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82(12):1046–1050
doi: 10.1093/jnci/82.12.1046
pubmed: 2348469
Pulvers JN, Marx G (2017) Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. Asia Pac J Clin Oncol 13(6):345–355
doi: 10.1111/ajco.12694
pubmed: 28653815
Ehrsson H, Wallin I, Yachnin J (2002) Pharmacokinetics of oxaliplatin in humans. Med Oncol 19(4):261–265
doi: 10.1385/MO:19:4:261
pubmed: 12512920
Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264
doi: 10.1093/annonc/mdt409
pubmed: 24256846
Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9(7):739–744
doi: 10.1023/A:1008344507482
pubmed: 9739440
Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6(3):225–236
doi: 10.1023/A:1026458604826
pubmed: 9226980
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K et al (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491
doi: 10.1007/s00520-009-0613-7
pubmed: 19330359
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139
doi: 10.1016/j.ejca.2005.02.012
pubmed: 15911236
Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A et al (2017) Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/alliance clinical trials. Support Care Cancer 25(11):3537–3544
doi: 10.1007/s00520-017-3780-y
pubmed: 28634656
pmcid: 5693734
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103–2114
doi: 10.1016/S0140-6736(11)60613-2
pubmed: 21641636
pmcid: 3159415
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317(23):2392–2401
doi: 10.1001/jama.2017.7105
pubmed: 28632865
pmcid: 5545896
Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. JCO 32(21):2240–2247
doi: 10.1200/JCO.2013.53.2473
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL et al (2014) Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 15(8):862–873
doi: 10.1016/S1470-2045(14)70227-X
pubmed: 24928083
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN et al (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307(13):1383–1393
doi: 10.1001/jama.2012.385
pubmed: 22474202
pmcid: 3442260
Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P et al (2023) Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage III colon cancer: findings from CALGB (alliance)/SWOG 80702. J Clin Oncol 41(5):1079–1091
doi: 10.1200/JCO.22.01637
pubmed: 36367997